KNSA Stock Analysis: Kiniksa Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 4.881m USD | 12M Return: 111.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.3M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is a London-headquartered biopharmaceutical company that develops and commercializes therapies targeting inflammatory and immune-mediated diseases, primarily in the United States, the United Kingdom, and other international markets. The company was incorporated in 2015 and went public in May 2018.
Its commercial product is ARCALYST, an interleukin-1 cytokine trap approved to treat recurrent pericarditis, a chronic autoinflammatory cardiovascular condition, with ongoing development also directed at cardiac sarcoidosis. Beyond its marketed asset, Kiniksa is advancing a pipeline that includes KPL-387, a fully human monoclonal antibody in Phase 2/3 trials for recurrent pericarditis, and KPL-116, an Fc-modified monoclonal antibody in pre-clinical development. The company was renamed Kiniksa Pharmaceuticals International, plc in June 2024.
As a clinical-stage and commercial-stage biotech, Kiniksa operates under a typical biopharmaceutical business model that relies on a single approved product to fund continued investment in a pipeline of biologic candidates, with revenue concentration risk offset by long patent protections and high development barriers to entry for competitors in biologics-based therapies.
- ARCALYST revenue accelerates with cardiac sarcoidosis label expansion
- KPL-387 Phase 2/3 data for recurrent pericarditis approaches
- Off-label IL-1 inhibitors compete with ARCALYST pricing power
| Net Income: 73.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 12.60 > 1.0 |
| NWC/Revenue: 58.03% < 20% (prev 53.75%; Δ 4.28% < -1%) |
| CFO/TA 0.20 > 3% & CFO 165.9m > Net Income 73.1m |
| Net Debt (-459.1m) to EBITDA (107.7m): -4.26 < 3 |
| Current Ratio: 3.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.4m) vs 12m ago 8.23% < -2% |
| Gross Margin: 54.63% > 18% (prev 54.34%; Δ 0.29% > 0.5%) |
| Asset Turnover: 105.9% > 50% (prev 80.28%; Δ 25.58% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.53 (Total Current Assets 594.2m - Total Current Liabilities 156.6m) / Total Assets 825.3m |
| B: -0.53 (Retained Earnings -439.5m / Total Assets 825.3m) |
| C: 0.15 (EBIT TTM 106.0m / Avg Total Assets 712.3m) |
| D: 2.76 (Book Value of Equity 605.7m / Total Liabilities 219.6m) |
| Altman-Z'' = 5.64 = AAA |
| DSRI: 0.37 (Receivables 23.2m/40.1m, Revenue 754.0m/481.2m) |
| GMI: 0.99 (GM 54.34% / 54.63%) |
| AQI: 0.69 (AQ_t 0.27 / AQ_t-1 0.39) |
| SGI: 1.57 (Revenue 754.0m / 481.2m) |
| TATA: -0.11 (NI 73.1m - CFO 165.9m) / TA 825.3m) |
| Beneish M = -3.34 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 60.94 with a total of 586,017 shares traded. Over the past week, the price has changed by -2.92%, over one month by +16.43%, over three months by +28.84% and over the past year by +111.60%.
Current recommended Stop Loss: 57.50 (which is 5.6% or 1.3 ATR below the current price).
Kiniksa Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy KNSA.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 66 | 8.3% |
P/E Trailing = 69.7143
P/E Forward = 57.8035
P/S = 6.473
P/B = 8.0585
Revenue TTM = 754.0m USD
EBIT TTM = 106.0m USD
EBITDA TTM = 107.7m USD
Long Term Debt = 5.86m USD (estimated: total debt 9.03m - short term 3.17m)
Short Term Debt = 3.17m USD (from shortTermDebt, last quarter)
Debt = 9.03m USD (from shortLongTermDebtTotal, last quarter) (leases 9.03m already included)
Net Debt = -459.1m USD (calculated: Debt 9.03m - CCE 468.1m)
Enterprise Value = 4.42b USD (4.88b + Debt 9.03m - CCE 468.1m)
Interest Coverage Ratio = unknown (Ebit TTM 106.0m / Interest Expense TTM 0.0)
EV/FCF = 26.92x (Enterprise Value 4.42b / FCF TTM 164.2m)
FCF Yield = 3.71% (FCF TTM 164.2m / Enterprise Value 4.42b)
FCF Margin = 21.78% (FCF TTM 164.2m / Revenue TTM 754.0m)
Net Margin = 9.69% (Net Income TTM 73.1m / Revenue TTM 754.0m)
Gross Margin = 54.63% ((Revenue TTM 754.0m - Cost of Revenue TTM 342.1m) / Revenue TTM)
Gross Margin QoQ = 55.02% (prev 54.93%)
Tobins Q-Ratio = 5.36 (Enterprise Value 4.42b / Total Assets 825.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.03m)
Taxrate = 31.07% (32.9m / 106.0m)
NOPAT = 73.1m (EBIT 106.0m * (1 - 31.07%))
Current Ratio = 3.79 (Total Current Assets 594.2m / Total Current Liabilities 156.6m)
Debt / Equity = 0.01 (Debt 9.03m / totalStockholderEquity, last quarter 605.7m)
Debt / EBITDA = -4.26 (Net Debt -459.1m / EBITDA 107.7m)
Debt / FCF = -2.80 (Net Debt -459.1m / FCF TTM 164.2m)
Total Stockholder Equity = 550.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.26% (Net Income 73.1m / Total Assets 825.3m)
RoE = 13.26% (Net Income TTM 73.1m / Total Stockholder Equity 550.9m)
RoCE = 19.04% (EBIT 106.0m / Capital Employed (Equity 550.9m + L.T.Debt 5.86m))
RoIC = 11.52% (NOPAT 73.1m / Invested Capital 634.1m)
WACC = 6.86% (E(4.88b)/V(4.89b) * Re(6.87%) + D(9.03m)/V(4.89b) * Rd(0.0%) * (1-Tc(0.31)))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.22 | Cagr: 5.76%
[DCF] Terminal Value 77.97% ; FCFF base≈116.0m ; Y1≈133.0m ; Y5≈195.8m
[DCF] Fair Price = 73.53 (EV 2.95b - Net Debt -459.1m = Equity 3.40b / Shares 46.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.73 | # QB: 0
Revenue Correlation: 98.47 | Revenue CAGR: 50.86% | SUE: 1.24 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.28 | Chg30d=-3.39% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.31 | Chg30d=-4.65% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.16 | Chg30d=-3.33% | Revisions=+0% | GrowthEPS=+54.7% | GrowthRev=+38.8%
EPS next Year (2027-12-31): EPS=1.70 | Chg30d=-3.13% | Revisions=+29% | GrowthEPS=+46.8% | GrowthRev=+20.6%
[Analyst] Revisions Ratio: +15% (up=6, down=4)